Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

N-Acetylcysteine (NAC)

N-Acetyl-L-Cysteine, a Glutathione Precursor for Sperm Quality

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
FDA-approved as a drug (acetaminophen antidote, mucolytic); sold OTC as a supplement with contested status

Reference only. Not medical advice.

What can go wrong

Oral NAC is generally well tolerated; nausea, vomiting, and diarrhea occur. It can potentiate nitroglycerin-induced hypotension and has been associated with rare bronchospasm in asthmatics. The FDA's position that NAC is not a lawful dietary ingredient (2020 warning letters, later softened by an enforcement-discretion policy) leaves its OTC status legally ambiguous.

This is something to take to a clinician. The Atlas can tell you what is known about n-acetylcysteine (nac) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

N-acetylcysteine is a cysteine donor that replenishes intracellular glutathione, the body's principal endogenous antioxidant, and directly scavenges reactive oxygen species implicated in sperm DNA damage. Randomized data, notably Safarinejad & Safarinejad (2009), report improved semen parameters and hormone profiles with 600 mg/day, and meta-analyses find gains in concentration, motility, and morphology. As with CoQ10, improvement in semen metrics has not translated into demonstrated live-birth benefit. In 2020 the FDA controversially asserted NAC is excluded from the definition of a supplement because it was first approved as a drug in 1963, creating regulatory uncertainty.

A hospital antidote repurposed as a fertility antioxidant, with the same live-birth caveat.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Idiopathic male subfertility (adjunct)
  • Post-varicocelectomy semen support
  • General antioxidant
  • Mucolytic and hepatoprotection (drug uses)

How it is supposed to work

NAC is deacetylated to L-cysteine, the rate-limiting substrate for glutathione synthesis. By boosting glutathione it defends sperm against oxidative stress, a recognized contributor to impaired motility and elevated sperm DNA fragmentation. Its free thiol group also directly reduces reactive oxygen species and can improve semen viscosity, which some trials cite as a mechanism for better motility.

Antioxidant does not equal fertility drug

The oxidative-stress theory of male infertility is sound, but supplementing antioxidants is a blunt instrument. Excess antioxidant load can theoretically cause reductive stress and impair the physiological ROS burst sperm need for capacitation and the acrosome reaction. Trials show parameter improvement; none prove that couples on NAC have more babies, and combination products make it impossible to credit NAC specifically.

What people get wrong

  • Often saidNAC boosts testosterone

    ActuallyOne trial noted hormonal shifts, but NAC is an antioxidant, not an androgen booster; the primary evidence is for semen parameters, not for raising T in eugonadal men.

  • Often saidIt is a proven fertility treatment

    ActuallyIt improves lab metrics in trials; live-birth benefit is not established and it does not replace treating correctable causes.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Set against the alternatives

NAC sits alongside CoQ10, carnitine, selenium, zinc, and lycopene in the antioxidant-for-fertility toolkit; it is cheaper than CoQ10 and often combined with selenium. None of these has cleared the live-birth bar.

What we do not know

  • Does NAC improve live-birth or only semen metrics?
  • Is there a reductive-stress ceiling above which antioxidants harm fertilization?
  • Will the FDA formally resolve NAC's supplement status?

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

NAC is a well-characterized synthetic compound; purity is generally high, but the 2020-2022 FDA status dispute prompted some retailers (including Amazon) to temporarily delist it, affecting availability rather than quality.

At a glance

Fertility dose
600 mg/day (trials)
Drug use
Acetaminophen overdose, mucolytic
Regulatory flag
FDA supplement-status dispute (2020-2022)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about N-Acetylcysteine (NAC). A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Safarinejad & Safarinejad, J Urol (selenium and/or NAC)2009

    NAC 600 mg improved semen parameters and gonadotropin/testosterone profile vs placebo

  • Ciftci et al., Urology (NAC in idiopathic infertility)2009

    Improved semen volume, motility, and viscosity

  • Jannatifar et al.2019

    NAC improved sperm parameters, chromatin integrity, and oxidative markers

  • Cochrane antioxidants for subfertile men2019

    Antioxidants overall: low-quality evidence, live-birth benefit uncertain